PET as a Translational Tool in Drug Development for Neuroscience Compounds. Issue 4 (24th February 2022)

• Record Type: Journal Article
• Authors: Varrone, Andrea; Bundgaard, Christoffer; Bang‐Andersen, Benny
• Is Part Of: Clinical pharmacology & therapeutics. Volume 111:Issue 4(2022)
• Page Start: 774
• Page End: 785
• Publication Date: 2022-02-24
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2548
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : In central nervous system drug discovery programs, early development of new chemical entities (NCEs) requires a multidisciplinary strategy and a translational approach to obtain proof of distribution, proof of occupancy, and proof of function in specific brain circuits. Positron emission tomography (PET) provides a way to assess in vivo the brain distribution of NCEs and their binding to the target of interest, provided that radiolabeling of the NCE is possible or that a suitable radioligand is available. PET is therefore a key tool for early phases of drug discovery programs. This review will summarize the main applications of PET in early drug development and discuss the usefulness of PET microdosing studies performed with direct labelling of the NCE and PET occupancy studies. The purpose of this review is also to propose an alignment of the nomenclatures used by drug metabolism and pharmacokinetic scientists and PET imaging scientists to indicate key pharmacokinetic parameters and to provide guidance in the performance and interpretation of PET studies.